Remove Avalon Remove Capital Remove Develop Remove Study
article thumbnail

Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup

Xconomy

Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).

Avalon 40
article thumbnail

Avelas Biosciences Gains $7.65M For Tumor Visualization

socalTECH

San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients.

Avalon 138
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Otonomy Raises $38.5M

socalTECH

San Diego-based Otonomy , a biopharmaceuticals firm developing products to treat disorders of the inner and middle ear, announced today that it has raised $38.5M The round was led by Novo Ventures and RiverVest Venture Partners, and also includes Domain Associates, TPG Biotech, and Avalon Ventures. in a Series B financing.

Avalon 150
article thumbnail

Otonomy Raises $10M

socalTECH

San Diego-based Otonomy , which is developing treatments for Meniere's disease, said today that it has raised $10M in a Series A financing round. The round came from Avalon Ventures. Otonomy is headed by Jay Lichter, who is also a managing director at Avalon Ventures. READ MORE>>.

Avalon 113
article thumbnail

Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent

Xconomy

and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday. Carmine Stengone.

Avalon 40
article thumbnail

Dauntless Takes Flight with New Business Model for Starting Biotechs

Xconomy

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. We really have a development focus,” Martin told me. “We We are taking capital as needed, not sooner.”.